0000000000247999

AUTHOR

Loretta Giuliano

0000-0003-2512-6972

showing 7 related works from this author

Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach

2021

Abstract Introduction Essential Tremor (ET) is increasingly recognized as a complex disorder with additional clinical signs other than tremor. It is still unknown whether a unique pathophysiologic or neurodegenerative process underlies progression and prognosis of the disease. The aim of the study was to identify ET phenotypes through a clinical-instrumental data-driven approach and to characterize possible patterns of neurodegeneration. Methods ET patients were categorized using spatio-temporal and kinematic variables related to mobility and dynamic stability processed by motion transducers. Differences between the identified groups in clinical-demographic variables, neuropsychological per…

0301 basic medicineRetinal degenerationMalemedicine.medical_specialtyHead tremorTimed up and go testRetina03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation80 and overNeurologicMedicineHumansCognitive DysfunctionGait DisordersCognitive declineNeurodegenerationTomographyGait Disorders NeurologicAgedAged 80 and overEssential tremorOptical coherence tomographybusiness.industryNeuropsychologyCognitionNeurodegenerative Diseasesmedicine.diseaseAction tremorGait030104 developmental biologyNeurologyOptical CoherenceEssential tremorFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryTomography Optical Coherence
researchProduct

Cardiovascular autonomic function and MCI in Parkinson's disease

2019

Abstract Introduction dysautonomic dysfunction and cognitive impairment represent the most disabling non-motor features of Parkinson's Disease (PD). Recent evidences suggest the association between Orthostatic Hypotension (OH) and PD-Dementia. However, little is known on the interactions between cardiovascular dysautonomia and Mild Cognitive Impairment (MCI). We aimed to evaluate the association between cardiovascular dysautonomia and MCI in patients with PD. Methods non-demented PD patients belonging to the PACOS cohort underwent a comprehensive instrumental neurovegetative assessment including the study of both parasympathetic and sympathetic function (30:15 ratio, Expiratory-Inspiratory …

Male0301 basic medicineAutonomic functionmedicine.medical_specialtyAutonomic systemParkinson's diseaseParkinson's diseasePrimary DysautonomiasDiseaseHypotension Orthostatic03 medical and health sciencesOrthostatic vital signs0302 clinical medicineInternal medicineHumansMedicineCognitive DysfunctionCognitive impairmentAgedRetrospective Studiesbusiness.industryMild cognitive impairmentDysautonomiaParkinson DiseaseMiddle Agedmedicine.disease030104 developmental biologyNeurologyCohortCardiologyFemaleCardiovascular dysautonomiaNeurology (clinical)Level iiGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment

2022

Background and purpose Parkinson's disease (PD) patients with cognitive impairment undergo progressive atrophy of several cortical and subcortical areas. The aim was to study the magnetic resonance imaging (MRI) morphometric features of PD patients with mild cognitive impairment (MCI). Methods Patients from the Parkinson's Disease Cognitive Impairment Study (PACOS) cohort with an available structural volumetric brain MRI and morphometric measurements of the midbrain and pons areas, middle cerebellar peduncle, superior cerebellar peduncle width and midbrain anteroposterior diameter (A-Pdiam) were included. MCI was diagnosed according to the Movement Disorder Society level II criteria. Additi…

Cerebral CortexMaleParkinson's diseaseParkinson DiseasemidbrainNeuropsychological TestsbrainstemNeurologyParkinson’s diseaseHumansmagnetic resonance imagingCognitive DysfunctionFemaleSettore MED/26 - NeurologiaNeurology (clinical)Atrophycognitive impairment
researchProduct

Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study

2022

Background: Polytherapy and the anticholinergic activity of several drugs negatively influence cognition in the elderly. However, little is known on the effect on Mild Cognitive Impairment (MCI) in Parkinson’s Disease (PD). Methods: Patients with PD belonging to the baseline PACOS cohort with full pharmacological data, have been included in this study. MCI diagnosis was made according to the MDS level II criteria. Polytherapy was defined as patients assuming ≥6 drugs. Anticholinergic burden has been calculated using the Anticholinergic Drug Scale (ADS). Molecules have been classified according to the ATC classification. Association with MCI has been assessed with a multivariate logistic re…

PharmacologyParkinson DiseaseGeneral MedicineMiddle AgedNeuropsychological TestspolytherapydrugsCholinergic Antagonistsanticholinergic burdenPsychiatry and Mental healthmild cognitive impairmentNeurologyParkinson’s diseaseHumansSettore MED/26 - NeurologiaCognitive DysfunctionPharmacology (medical)Neurology (clinical)polypharmacyAgedCurrent Neuropharmacology
researchProduct

Neuroanatomical changes in early Parkinson’s disease with mild cognitive impairment: a VBM study; the Parkinson’s Disease Cognitive Impairment Study …

2021

Introduction: Mild cognitive impairment (MCI) is common in Parkinson’s disease (PD), but the underlying pathological mechanism has not been fully understood. Voxel-based morphometry could be used to evaluate regional atrophy and its relationship with cognitive performances in early PD-MCI. Patients and Methods: One hundred and six patients with PD were recruited from a larger cohort of patients, the Parkinson’s Disease Cognitive Impairment Study (PaCoS). Subject underwent a T1-3D MRI and a complete clinical and neuropsychological evaluation. Patients were divided into PD with normal cognition (PD-NC) and PD-MCI according to the MDS level II criteria–modified for PD-MCI. A subgroup of early …

medicine.medical_specialtyParkinson's diseasePrecuneusInferior frontal gyrusDermatologyNeuropsychological TestsAudiologybehavioral disciplines and activitiesVoxel-based morphometry (VBM)Angular gyrus03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansCognitive DysfunctionMagnetic resonance imaging (MRI)030212 general & internal medicineGray MatterMild cognitive impairment (MCI)business.industryNeuropsychologyBrainSettore MED/37 - NeuroradiologiaGeneral MedicineFrontal gyrusmedicine.diseaseMagnetic Resonance ImagingParkinson diseasePsychiatry and Mental healthmedicine.anatomical_structurenervous systemSuperior frontal gyrusSettore MED/26 - NeurologiaNeurology (clinical)Settore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMild cognitive impairment (MCI)030217 neurology & neurosurgeryNeurological Sciences
researchProduct

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study

2019

Abstract Introduction Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Methods From the PaCoS (Parkinson's disease Cognitive impairment Study) cohort, a sample of 102 subjects including 46 PD-MCI and 56 PD with normal cognition (PD-NC) was selected based on…

Male0301 basic medicinemedicine.medical_specialtyParkinson's diseaseQuantitative EEGElectroencephalographyAudiology03 medical and health sciences0302 clinical medicinemental disordersmedicineHumansDementiaCognitive DysfunctionNeuropsychological assessmentCognitive declineTomographyAgedElectrocortical networkElectrocortical networksmedicine.diagnostic_testbusiness.industryParietal lobeMild cognitive impairmentElectroencephalographyParkinson DiseaseCognitionMiddle Agedmedicine.disease030104 developmental biologyNeurologyFrontal lobeDisease ProgressionFemaleNeurology (clinical)Nerve NetElectrocortical networks; Mild cognitive impairment; Parkinson's disease; Quantitative EEG; Neurology; Geriatrics and Gerontology; Neurology (clinical)Geriatrics and GerontologyOccipital lobebusiness030217 neurology & neurosurgeryParkinsonism & Related Disorders
researchProduct

Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRI…

2022

Objective: Post-stroke epilepsy (PSE) is one of the most common causes of acquired epilepsy and accounts for about 10-15% of all newly diagnosed epilepsy cases. However, evidence about the clinical profile of antiseizure medications in the PSE setting is currently limited. Brivaracetam (BRV) is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A. The aim of this study was to assess the 12-month effectiveness and tolerability of adjunctive BRV in patients with PSE treated in a real-world setting. Methods: This was a subgroup analysis of patients with PSE included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). The BRIVAFI…

AdultAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; StrokeCerebrovascular diseasesSettore MED/26Antiseizure medication Brivaracetam Focal seizures Stroke Cerebrovascular diseasesFocal seizuresDouble-Blind MethodDrug TherapySeizuresHumansAgedRetrospective StudiesAntiseizure medicationEpilepsyGeneral MedicineMiddle AgedPyrrolidinonesStrokeTreatment OutcomeNeurologyItalyCombinationBrivaracetamAntiseizure medication; Brivaracetam; Cerebrovascular diseases; Focal seizures; Stroke; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Middle Aged; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Epilepsy; StrokeDrug Therapy CombinationAnticonvulsantsNeurology (clinical)
researchProduct